Ultime notizie per CHS (NASDAQ:CHSCN) Azioni

CHS Inc is an integrated agricultural enterprise, that provides grain, food and energy resources to businesses and consumers. Its Energy segment produces and provides wholesale distribution of petroleum products and transportation of those products. Its Ag segment, which is the key revenue driver, purchases and processes or resells grains and oilseeds; serves as a wholesaler and retailer of crop inputs; produces and markets ethanol. Its Nitrogen Production segment consists of equity method investment in CF Nitrogen, which entitles to the purchase of up to a specified quantity of granular urea and UAN annually from CF Nitrogen. Maximum revenue is generated from Ag segment.

Cum Red Pfd Registered Shs -B- Series -2-

CHS Inc - Preferred Class B Series 2 Reset Rate

CHS Inc

HC Wainwright &amp; Co. analyst Heiko Ihle reiterates DRDGold (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRD#NYSE">DRD</a>) with a Buy and maintains $13.25 price target.

News

Price Target

Reiteration

Analyst Ratings

HC Wainwright & Co. Reiterates Buy on DRDGold, Maintains $13.25 Price Target

Management

CVS Naming Caremark President David Joyner As Its New CEO

HC Wainwright &amp; Co. analyst Heiko Ihle reiterates Avino Silver &amp; Gold Mines (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ASM#AMEX">ASM</a>) with a Buy and maintains $1.5 price target.

HC Wainwright & Co. Reiterates Buy on Avino Silver & Gold Mines, Maintains $1.5 Price Target

Biotech

Large Cap

Health Care

General

The European Medicines Agency's Committee For Medicinal Products For Human Use Has Adopted A Positive Opinion, Recommending Approval Of Novo Nordisk's Alhemo (Concizumab) As The First Once-Daily Subcutaneous Prophylactic Treatment For People Aged 12 Years Or Older With Hemophilia A Or B With Inhibitors.

HC Wainwright &amp; Co. analyst Heiko Ihle reiterates First Majestic Silver (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AG#NYSE">AG</a>) with a Buy and maintains $8.5 price target.

HC Wainwright & Co. Reiterates Buy on First Majestic Silver, Maintains $8.5 Price Target

The combined companies for the trailing twelve months have generated $235 million in revenue, increasing approximately&nbsp;25%&nbsp;quarter-over-quarter.

Guidance

BTTR

Better Choice Expects Combined 2025 Pro Forma Basis Revenue And EBITDA To Be Approximately +$270M, And +$10M, Respectively

Better Choice Says Continues To Make Progress Towards Closing Of Its Acquisition Of SRx Health Solutions; Expects Transaction To Close In Late Q4 Of This Year Or Early Q1 Of 2025

Needham analyst Ami Fadia reiterates Neumora Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMRA#NASDAQ">NMRA</a>) with a Buy and maintains $23 price target.

NMRA

Needham Reiterates Buy on Neumora Therapeutics, Maintains $23 Price Target

Based on sales trends and order intake in recent years, it expects further market share gains with domestic Chinese OEMs in the coming years.
With the seasonally strong fourth quarter remaining of the year, it reaffirms&nbsp;guidance of around 9.5-10.0% adjusted operating margin for 2024, but to be at the low end of this range.
&nbsp;

Autoliv Now Expects Full Year 2024 Organic Sales Growth To Be 1% Instead Of Previously Expected 2% Due To Unfavorable Market Mix Development

Regions Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RF#NYSE">RF</a>) reported quarterly earnings of $0.57 per share which beat the analyst consensus estimate of $0.53 by 7.55 percent. This is a 16.33 percent increase over earnings of $0.49 per share from the same period last year. The company reported quarterly sales of $1.87 billion which beat the analyst consensus estimate of $1.80 billion by 3.78 percent. This is a 0.54 percent increase over sales of $1.86 billion the same period last year.

Earnings

Earnings Beats

Regions Finl Q3 Adj $0.57 Beats $0.53 Estimate, Sales $1.87B Beat $1.80B Estimate

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Buy and maintains $400 price target.

ALNY

HC Wainwright & Co. Reiterates Buy on Alnylam Pharmaceuticals, Maintains $400 Price Target

Autoliv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALV#NYSE">ALV</a>) reported quarterly earnings of $1.84 per share which missed the analyst consensus estimate of $1.95 by 5.64 percent. The company reported quarterly sales of $2.56 billion which beat the analyst consensus estimate of $2.53 billion by 0.89 percent. This is a 1.58 percent decrease over sales of $2.60 billion the same period last year.

Earnings Misses

Autoliv Q3 2024 Adj EPS $1.84 Misses $1.95 Estimate, Sales $2.56B Beat $2.53B Estimate

HC Wainwright &amp; Co. analyst Amit Dayal reiterates Gevo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEVO#NASDAQ">GEVO</a>) with a Buy and maintains $14 price target.

GEVO

HC Wainwright & Co. Reiterates Buy on Gevo, Maintains $14 Price Target

Needham analyst Ami Fadia reiterates Avadel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVDL#NASDAQ">AVDL</a>) with a Buy and maintains $22 price target.

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

Needham Reiterates Buy on Avadel Pharmaceuticals, Maintains $22 Price Target

Needham analyst Mayank Tandon maintains WNS (Hldgs) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WNS#NYSE">WNS</a>) with a Buy and lowers the price target from $70 to $60.

Needham Maintains Buy on WNS (Hldgs), Lowers Price Target to $60

Needham analyst Kyle Peterson reiterates Equifax (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EFX#NYSE">EFX</a>) with a Buy and maintains $350 price target.

Needham Reiterates Buy on Equifax, Maintains $350 Price Target

Needham analyst Mike Matson downgrades Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) from Buy to Hold and maintains the price target from $86 to $86.

Downgrades

Needham Downgrades Boston Scientific to Hold, Maintains Price Target to $86

<a href="https://www.reuters.com/technology/apples-new-iphone-sales-china-jump-20-first-3-weeks-counterpoint-says-2024-10-18/" title="https://www.reuters.com/technology/apples-new-iphone-sales-china-jump-20-first-3-weeks-counterpoint-says-2024-10-18/">https://www.reuters.com/technology/apples-new-iphone-sales-china-jump-20-first-3-weeks-counterpoint-says-2024-10-18/</a>

Tech

AAPL

Reported Earlier, Apple's New iPhone Sales In China Rose 20% In First 3 Weeks

EV <a href="https://www.benzinga.com/news/24/10/41223011/rivians-production-guidance-cut-spurred-by-miscommunication-with-atlanta-based-supplier-resulting-in">startup</a> Rivian Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) said on Thursday that it will launch its Halloween software update starting Oct. 18, complete with spooky features and car costumes.
What Happened: The company announced the update in a video posted on social media platform X featuring actor David Hasselhoff who starred in the Knight Rider series.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">An iconic duo reunited <a href="https://twitter.com/DavidHasselhoff?ref_src=twsrc%5Etfw">@DavidHasselhoff</a>.⁰ The countdown is on. Our Halloween software update arrives after the clock strikes midnight (local). Spooky features will be available for a limited time. <a href="https://t.co/hdKV0z4WIC">pic.twitter.com/hdKV0z4WIC</a>
&mdash; Rivian (@Rivian) <a href="https://twitter.com/Rivian/status/1846945663860572411?ref_src=twsrc%5Etfw">October 17, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
One of the car costumes available with the update is inspired by Knight Rider. The costume will alter the Rivian&#8217;s interior display system and the exterior lightbar on Gen 2 R1 vehicles will cascade a red beam to replicate the experience of K.I.T.T, the robotic automobile that featured in the series.
There are also other car costumes available with the update, inspired by iconic and classic vehicles from pop culture, such as one inspired by the time machine in Universal Pictures and Amblin Entertainment's Back to the Future, in addition to a spooky option. 
The haunted Rivian car costume has eight different sound effects and three different color themes to choose from ranging between purple, yellow, red, and green. The interior display screen will feature static and ghosts to increase the spooky feeling when the vehicle is parked with the costume. 
Besides Costumes: Besides costumes, Rivian&#8217;s new update changes pedestrians on the driver display to zombies and bicyclists and motorcyclists into headless horsemen. 
Vehicle owners can also play multiple spooky chirp sounds, including one resembling the owl. 
However, the spooky features will only be available for a limited time until November 4, the company warned. Additionally, <a href="https://www.benzinga.com/news/24/08/40574576/rivian-or-lucid-which-of-the-two-loss-making-ev-startups-is-solving-cash-burn">both the vehicle</a> and the Rivian mobile app must be updated to their latest versions for the features, it added.
Check out more of Benzinga&#8217;s Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link</a>.
Read More:
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41324450/elon-musk-says-spacexs-next-generation-starlink-satellites-will-be-so-big-that-only-starship-can-lau" target="_blank" rel="noreferrer noopener">Elon Musk Says SpaceX's Next-Generation Starlink Satellites Will Be ‘So Big That Only Starship Can Launch Them'</a></li>
</ul>
Photo courtesy: Rivian

RIVN

Trick Or Treat: Rivian Rolls Out Spooky Halloween Update Featuring Car Costumes, Creepy Chirps

China-based U.S.-listed stocks experienced a notable pre-market rally on Friday, driven by China&#8217;s better-than-expected GDP figures for the third quarter.
What Happened: Several major Chinese companies saw significant gains. As per <a href="https://pro.benzinga.com">Benzinga Pro</a>, Alibaba Group Holding Ltd &#8211; ADR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) rose by 3.23%, while its rival PDD Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>) increased by 5.38%. Baidu Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>) climbed 4.23%, and JD.Com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>) was up 5.05%. In the electric vehicle sector, Nio Inc &#8211; ADR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) and Li Auto Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LI#NASDAQ">LI</a>) saw increases of 5.44% and 6.48%, respectively.
China&#8217;s GDP grew by 4.6% year-over-year in the third quarter, surpassing expectations from a Reuters poll, though slightly below the 4.7% growth in the previous quarter. As per CNBC, this marks the slowest growth rate since mid-last year, moving further from Beijing&#8217;s 5% annual target. 
Retail sales in September grew by 3.2% year-on-year, exceeding forecasts, and industrial output rose by 5.4%, also surpassing expectations. However, house prices fell by 5.8% year-over-year in September, a larger decline than the 5.3% drop in August. Meanwhile, the CSI 300 index in Mainland China surged 3.62% to close at 3,925.23, after hitting an intraday high of 5.5%.
See Also: <a href="https://www.benzinga.com/news/24/10/41325447/after-pulling-down-oil-prices-with-weak-demand-china-urges-israel-iran-to-avoid-vicious-circle-of-co?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">After Pulling Down Oil Prices With Weak Demand, China Urges Israel, Iran To Avoid &#8216;Vicious Circle&#8217; Of Conflict</a>
Why It Matters: The recent economic data comes amid China&#8217;s efforts to stave off a potential economic downturn. In late September, China announced a <a href="https://www.benzinga.com/markets/equities/24/10/41182930/china-was-tipping-into-a-japan-style-lost-decade-of-deflation-and-stagnation-before-late-septemb">series of stimulus measures,</a> including a 50 basis-point cut to the mandatory reserve ratio and a reduction in the benchmark policy rate by 0.2 percentage points. The People's Bank of China also reduced rates on existing mortgages and lowered the minimum down payment on second homes. Despite these efforts, investor sentiment remained cautious, as the absence of a<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41316058/chinese-stocks-etfs-struggle-as-multi-trillion-yuan-stimulus-hopes-fall-short-yet-m"> large-scale economic package</a> left traders underwhelmed. 
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41316396/lululemon-fresh-and-unique-shows-promise-thanks-to-china-opportunity-growth-push-sa?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Lululemon &#8216;Fresh And Unique,&#8217; Shows Promise Thanks To China Opportunity, Growth Push Say Analysts</a></li>
</ul>
Disclaimer: This content was partially produced with the help of <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a> and was reviewed and published by Benzinga editors.
Image via Shutterstock

Comments

CHS

Notizie

Ultime notizie per CHS (NASDAQ:CHSCN) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO